SBIO vs. NLR
SBIO (ALPS Medical Breakthroughs ETF) and NLR (VanEck Uranium and Nuclear ETF) are both exchange-traded funds - SBIO is a Health & Biotech Equities fund tracking the S-Network Medical Breakthroughs Index, while NLR is a Alternative Energy Equities fund tracking the MVIS Global Uranium & Nuclear Energy Index. Both are passively managed. Over the past 10 years, SBIO returned 8.36%/yr vs 12.72%/yr for NLR. At a 0.31 correlation, their price movements are largely independent. SBIO charges 0.50%/yr vs 0.56%/yr for NLR.
Performance
SBIO vs. NLR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO achieves a -1.72% return, which is significantly lower than NLR's -0.79% return. Over the past 10 years, SBIO has underperformed NLR with an annualized return of 8.36%, while NLR has yielded a comparatively higher 12.72% annualized return.
SBIO
- 1D
- -0.36%
- 1M
- -9.33%
- YTD
- -1.72%
- 6M
- -2.48%
- 1Y
- 59.38%
- 3Y*
- 16.69%
- 5Y*
- 1.33%
- 10Y*
- 8.36%
NLR
- 1D
- 0.91%
- 1M
- -12.54%
- YTD
- -0.79%
- 6M
- -6.08%
- 1Y
- 26.72%
- 3Y*
- 31.16%
- 5Y*
- 20.16%
- 10Y*
- 12.72%
SBIO vs. NLR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | -1.72% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 50.30% | -11.81% | 45.67% |
NLR VanEck Uranium and Nuclear ETF | -0.79% | 56.50% | 14.26% | 36.67% | 2.29% | 13.63% | 3.49% | 0.20% | 4.94% | 8.25% |
Correlation
The correlation between SBIO and NLR is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.33 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.39 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2015 | 0.31 |
SBIO vs. NLR - Sectors Allocation Comparison
Sectors
SBIO
NLR
Healthcare
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
Industrials
-
Real Estate
-
-
Technology
-
Utilities
-
Financial Services
-
Healthcare
SBIO
NLR
-
Basic Materials
SBIO
-
NLR
-
Communication Services
SBIO
-
NLR
-
Consumer Cyclical
SBIO
-
NLR
-
Consumer Defensive
SBIO
-
NLR
-
Energy
SBIO
-
NLR
Industrials
SBIO
-
NLR
Real Estate
SBIO
-
NLR
-
Technology
SBIO
-
NLR
Utilities
SBIO
-
NLR
Financial Services
SBIO
NLR
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO vs. NLR — Risk / Return Rank
SBIO
NLR
SBIO vs. NLR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and VanEck Uranium and Nuclear ETF (NLR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO | NLR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.39 | ||
| Sortino ratioReturn per unit of downside risk | +1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.13 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 4.72 | 1.04 | +3.67 |
| Martin ratioReturn relative to average drawdown | 13.54 | 2.08 | +11.46 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO | NLR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.02 | 0.63 | +1.39 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.04 | 0.69 | -0.65 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.25 | 0.53 | -0.28 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.16 | +0.05 |
Drawdowns
SBIO vs. NLR - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, roughly equal to the maximum NLR drawdown of -65.05%. Use the drawdown chart below to compare losses from any high point for SBIO and NLR.
Loading charts...
Drawdown Indicators
| SBIO | NLR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.06% | -65.05% | +1.99% |
Max Drawdown (1Y)Largest decline over 1 year | -12.66% | -25.80% | +13.14% |
Max Drawdown (3Y)Largest decline over 3 years | -42.44% | -30.48% | -11.96% |
Max Drawdown (5Y)Largest decline over 5 years | -53.10% | -30.48% | -22.62% |
Max Drawdown (10Y)Largest decline over 10 years | -63.06% | -34.35% | -28.71% |
Current DrawdownCurrent decline from peak | -17.90% | -25.03% | +7.13% |
Average DrawdownAverage peak-to-trough decline | -28.43% | -35.71% | +7.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.40% | 12.87% | -8.47% |
Volatility
SBIO vs. NLR - Volatility Comparison
The current volatility for ALPS Medical Breakthroughs ETF (SBIO) is 9.87%, while VanEck Uranium and Nuclear ETF (NLR) has a volatility of 13.36%. This indicates that SBIO experiences smaller price fluctuations and is considered to be less risky than NLR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO | NLR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.87% | 13.36% | -3.49% |
Volatility (6M)Calculated over the trailing 6-month period | 22.68% | 33.24% | -10.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.62% | 42.96% | -13.34% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.56% | 29.43% | +4.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.18% | 24.14% | +9.04% |
SBIO vs. NLR - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than NLR's 0.56% expense ratio.
Dividends
SBIO vs. NLR - Dividend Comparison
SBIO has not paid dividends to shareholders, while NLR's dividend yield for the trailing twelve months is around 2.57%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NLR VanEck Uranium and Nuclear ETF | 2.57% | 2.55% | 0.76% | 4.54% | 2.02% | 1.99% | 2.23% | 2.21% | 3.91% | 4.86% | 3.62% | 3.30% |
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% | 0.00% | 0.00% |
Frequently Asked Questions
SBIO and NLR have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NLR has higher volatility (13.36%) compared to SBIO (9.87%). In terms of maximum drawdown, SBIO dropped -63.06% vs NLR's -65.05%.
On 10-year performance, NLR leads with 12.72% vs 8.36% for SBIO. On fees, SBIO is cheaper at 0.50% per year. On volatility, SBIO has been the lower-risk option at 9.87%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, NLR has performed better with a 12.72% return vs 8.36%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
SBIO is cheaper with a 0.50% expense ratio, compared with 0.56% for NLR.
NLR has the higher dividend yield at 2.57%, compared with 0.00% for SBIO.
SBIO is categorized as Health & Biotech Equities, while NLR is Alternative Energy Equities. SBIO tracks S-Network Medical Breakthroughs Index, while NLR tracks MVIS Global Uranium & Nuclear Energy Index. They also come from different issuers: SS&C and VanEck. Their fees differ too: 0.50% for SBIO and 0.56% for NLR.
SBIO currently has the higher Sharpe Ratio (2.02 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SBIO and NLR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer